GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioXcel Therapeutics Inc (FRA:BX2) » Definitions » Float Percentage Of Total Shares Outstanding

BioXcel Therapeutics (FRA:BX2) Float Percentage Of Total Shares Outstanding : 75.92% (As of May. 21, 2024)


View and export this data going back to 2018. Start your Free Trial

What is BioXcel Therapeutics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, BioXcel Therapeutics's float shares is 28.49 Mil. BioXcel Therapeutics's total shares outstanding is 37.53 Mil. BioXcel Therapeutics's float percentage of total shares outstanding is 75.92%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, BioXcel Therapeutics's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, BioXcel Therapeutics's Institutional Ownership is 19.14%.

BioXcel Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

BioXcel Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=28.49/37.53
=75.92%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioXcel Therapeutics (FRA:BX2) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioXcel Therapeutics Inc (FRA:BX2) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
TRVI CARM TNYA ACRV CTXR CDT PBYI DSGN TSVT TALS OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
BTAI:USA BX2:Germany
Address
555 Long Wharf Drive, 12th Floor, New Haven, CT, USA, 06511
Website
https://www.bioxceltherapeutics.com
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

BioXcel Therapeutics (FRA:BX2) Headlines

No Headlines